ATOSSA THERAPEUTICS, INC. Accounts Receivable, Allowance for Credit Loss
ATOSSA THERAPEUTICS, INC. (ATOS) had Accounts Receivable, Allowance for Credit Loss of $1.18 million as of 2015-09-30, per its 10-Q filed 2015-11-12.
Discontinued › Balance Sheet › Assets
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2015-11-12
- 2015-09-30: Accounts Receivable, Allowance for Credit Loss $1.18M.
- 2014-12-31: Accounts Receivable, Allowance for Credit Loss $564.46K; Accounts Receivable, Allowance for Credit Loss as first filed $564.15K.
- 2014-03-31: Accounts Receivable, Allowance for Credit Loss $382.72K.
- 2013-12-31: Accounts Receivable, Allowance for Credit Loss $354.86K; Accounts Receivable, Allowance for Credit Loss as first filed $354.86K.
| Period end | Accounts Receivable, Allowance for Credit Loss | Accounts Receivable, Allowance for Credit Loss as first filed |
|---|---|---|
| 2015-09-30 | $1.18M 10-Q · filed 2015-11-12 | |
| 2014-12-31 | $564.46K 10-Q · filed 2015-11-12 | $564.15K 10-K · filed 2015-03-30 |
| 2014-03-31 | $382.72K 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $354.86K 10-K · filed 2015-03-30 | $354.86K 10-K · filed 2014-03-27 |
| 2013-09-30 | $228.84K 10-Q · filed 2013-11-12 | |
| 2012-12-31 | $0.00 10-K · filed 2014-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |